Karyopharm Therapeutics
KPTI
168 hedge funds and large institutions have $987M invested in Karyopharm Therapeutics in 2020 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 21 closing their positions.
52% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 21
40% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $7.99M
39% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 44
7% more funds holding
Funds holding: 157 → 168 (+11)
4% more capital invested
Capital invested by funds: $949M → $987M (+$38.7M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.13% less ownership
Funds ownership: 5.91% → 5.78% (-0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$36M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$12.8M |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$9.27M |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.51M |
| 5 |
Alkeon Capital Management
New York
|
+$7.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$87.6M |
| 2 |
Two Sigma Investments
New York
|
-$19.3M |
| 3 |
D.E. Shaw & Co
New York
|
-$15.5M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.6M |
| 5 |
Two Sigma Advisers
New York
|
-$10.5M |
KPTI Hedge Fund Activity: Q4 2020 in Review
168 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2020, worth a combined $987M — up 4.1% from $949M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new KPTI positions and 21 closed out — a net gain of 11 holders — while 61 added to existing stakes and 44 trimmed.
The largest buyer was Millennium Management, adding an estimated $36M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $87.6M sold.
- 168 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2020, up from 157 in Q3 2020.
- Funds reported $987M of Karyopharm Therapeutics stock for Q4 2020, up 4.1% quarter-over-quarter.
- 32 funds opened new Karyopharm Therapeutics positions in Q4 2020 and 21 closed out, a net change of +11 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2020 was Millennium Management, an estimated $36M added.
- The largest Karyopharm Therapeutics seller in Q4 2020 was Avoro Capital Advisors, an estimated $87.6M sold.
Based on aggregated 13F filings for Q4 2020.